Details of Disease

General Information of Disease (ID: DISWGS0R)

• Disease Name: Non-muscle invasive bladder cancer
• Disease Class: 2C94: Bladder cancer
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISWGS0R: Non-muscle invasive bladder cancer
• ICD Code:
  ICD-11: ICD-11: 2C94
  ICD-10: ICD-10: C67, C67.9
  ICD-9: ICD-9: 188
  Expand ICD-9: 188

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apaziquone	DMVY0BU	Phase 3	Small molecular drug	[1]
CG0070	DM7MADA	Phase 3	Oncolytic virus therapy	[2]
EN3488	DMZID5A	Phase 3	NA	[3]
Sasanlimab	DMUVSG4	Phase 3	Antibody	[4]
ABI-009	DMQ6KZM	Phase 2	NA	[5]
ALT-801	DM9KL7P	Phase 2	NA	[5]
Vesimune	DM7S4NP	Phase 1	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT00598806) Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant for Noninvasive Bladder Cancer. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04452591) Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00406068) Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04165317) Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)